Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes
- 1 February 2012
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 68 (7) , 1033-1042
Abstract
To search for a relationship between ultra-rapid metabolism catalysed by cytochrome P450 2C9 (CYP2C9) and its genotypes.Keywords
This publication has 29 references indexed in Scilit:
- CYP2C9 Amino Acid Residues Influencing Phenytoin Turnover and Metabolite Regio- and StereochemistryThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Becker muscular dystrophy caused by an intronic mutation reducing the efficiency of the splice donor site of intron 26 of the dystrophin geneNeuromuscular Disorders, 2009
- A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapyBlood Cells, Molecules, and Diseases, 2009
- Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: A 6-month follow-up studyXenobiotica, 2008
- A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparationsRapid Communications in Mass Spectrometry, 2007
- Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and KoreansEuropean Journal of Clinical Pharmacology, 2007
- Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in JapanesePharmacogenetics and Genomics, 2006
- haplotype structure in European American warfarin patients and association with clinical outcomesClinical Pharmacology & Therapeutics, 2005
- The karolinska cocktail for phenotyping of five human cytochrome P450 enzymesClinical Pharmacology & Therapeutics, 2003
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996